Our federal lawmakers should substantial and sustained investments for Alzheimer’s research funding and the dementia public ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

ALIA-1758 is in the same general class as Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), which have started to roll out in markets around the world but are seeing ...